Microsoft word - spc100813
1 NAME OF THE MEDICINAL PRODUCT
Phenytoin Injection B.P. 250mg/5ml.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5ml contains Phenytoin Sodium B.P. 250mg.
3 PHARMACEUTICAL FORM
Clear, colourless, particle free solution intended for parenteral administration to human
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Phenytoin Injection B.P. is indicated for the control of status epilepticus of the tonic
clonic (grand mal) type and prevention and treatment of seizures occurring during or
following neurosurgery and/or severe head injury.
4.2 Posology and method of administration
Method of administration: Intravenous. Intramuscular.
Solutions for parenteral administration should be inspected visually for particulate matter
and discoloration prior to use.
Only a clear solution should be used and the product should be discarded if a precipitate
or haziness develops in the solution. On refrigeration or freezing, a precipitate might
form, but this will dissolve when the solution is allowed to stand at room temperature.
The product is still suitable for use. Only a clear solution should be used. A faint yellow
discoloration may develop, but this does not affect the potency of the solution.
There is a relatively small margin between full therapeutic effect and minimally toxic
doses of this drug. Optimum control without clinical signs of toxicity can most often be
achieved with serum levels in the range 10 - 20mg/l (40 - 80 micromoles/l).
Phenytoin Injection B.P. should be injected slowly directly into a large vein through a
large-gauge needle or intravenous catheter. Because of the alkalinity of the solution, each
injection or infusion of phenytoin should be preceded and followed by an injection of
sterile saline through the same needle or catheter to avoid local venous irritation.
For administration by intravenous infusion phenytoin injection should be diluted in 50 -
100 ml of normal saline, and the final concentration of phenytoin in the solution should
not exceed 10 mg/ml. Administration should commence immediately after the mixture
has been prepared and must be completed within one hour (the infusion mixture should not be refrigerated). An in-line filter (0.22 - 0.50 microns) should be used. The diluted form is suitable for use as long as it remains free of haziness and precipitate. Continuous monitoring of the electrocardiogram and blood pressure is essential and the patient should be observed for signs of respiratory depression. Cardiac resuscitative equipment should be available. If administration of intravenous phenytoin does not terminate seizures, the use of other measures, including general anaesthesia should be considered. Adults : Status epilepticus :
In a patient having continuous seizure activity, as compared to the more common rapidly recurring seizures, i.e. serial epilepsy, intravenous diazepam or a short-acting barbiturate is recommended prior to administration of phenytoin because of the more rapid onset of action of the former. Following the use of diazepam in patients having continuous seizures and in the initial management of serial epilepsy a loading dose of phenytoin 10 - 15mg/kg should be injected slowly intravenously, at a rate not exceeding 50mg per minute (this will require approximately 20 minutes in a 70kg patient). The loading dose should be followed by maintenance doses of 100mg orally or intravenously every 6 to 8 hours. Studies in neonates have shown that absorption of phenytoin is unreliable after oral administration, but a loading dose of 15 - 20mg/kg of phenytoin intravenously will usually produce serum concentrations of phenytoin within the generally accepted therapeutic range (10 - 20mg/l). The drug should be injected slowly intravenously at a rate of 1 - 3mg/kg/min. Determination of phenytoin serum levels is advised during use in the management of status epilepticus and subsequently whilst establishing maintenance dosage. The clinically effective range is usually 10- 20mg/l although some cases of tonic-clonic seizures may be controlled with lower serum levels of phenytoin. Intramuscular administration should not be used in the treatment of status epilepticus because peak plasma levels may not be reached for up to 24 hours. Other clinical conditions:
It is not possible to provide a universally applicable dosage schedule. The intravenous route of administration is preferred. Dosage and dosing interval will be determined by the needs of the individual patient and factors such as previous anti-epileptic therapy, seizure control, age and general medical condition must be considered. Although absorption of phenytoin is slow following i.m. injection, such use may be appropriate in certain conditions.
When short term intramuscular administration is necessary for a patient previously
stabilised orally, compensating dosage adjustments are essential to maintain therapeutic
serum levels. An intramuscular dose 50% greater than the oral dose is required to
maintain these levels. When returned to oral administration, the dose of phenytoin should
be reduced by 50% of the original oral dose for the same period of time the patient
received phenytoin intramuscularly, to prevent excessive serum levels due to continued
release from intramuscular injection sites. Neurosurgery:
In a patient who has not previously received the drug, Phenytoin Injection
B.P. 100 - 200mg (2 - 4ml) may be given intramuscularly at approximately 4-hour
intervals prophylactically during neurosurgery and continued during the postoperative
period for 48 - 72 hours. The dosage should then be reduced to a maintenance dose of
300mg and adjusted according to serum level estimations.
If possible, intramuscular injections of phenytoin should not be continued for more than
one week; after this, alternative routes such as naso-gastric intubation should be
considered. For time periods less than one week, the patient switched from intramuscular
administration should receive one half the original oral dose for the same period of time
the patient received phenytoin intramuscularly. Serum levels are valuable as a guide to an
appropriate adjustment of dosage. Elderly:
Elderly (over 65 years): As for adults. It should be noted that complications may
occur more readily in elderly patients. Neonates:
Studies in neonates have shown that absorption of phenytoin is unreliable after
oral administration, but a loading dose of 15 - 20mg/kg of phenytoin intravenously will
usually produce serum concentrations of phenytoin within the generally accepted
therapeutic range (10 - 20mg/l). The drug should be injected slowly intravenously at a
rate of 1 - 3mg/kg/min. Infants and children:
As for adults. Children tend to metabolise phenytoin more rapidly
than adults and this should be borne in mind when determining dosage regimens.
Monitoring of phenytoin serum levels is especially helpful. 4.3 Contraindications
Phenytoin is contra-indicated in patients who are hypersensitive to phenytoin or other
hydantoins. It is also contra-indicated in sinus bradycardia, sino-atrial block, and second
and third degree A-V block, and patients with Adams Stokes syndrome. Intra-arterial
injection must be avoided because of the high pH of the solution. 4.4 Special warnings and precautions for use
In adults, intravenous administration should not exceed a rate of 50mg per minute. In neonates, phenytoin should be administered at a rate of 1 - 3mg/kg/min. The most significant signs of toxicity with the intravenous use of phenytoin are cardiovascular collapse and/or central nervous system depression. Severe cardiotoxic reactions and fatalities due to depression of atrial and ventricular conduction and ventricular fibrillation, respiratory arrest and tonic seizures have been reported,
particularly in elderly or gravely ill patients, if the preparation is given too rapidly or in excess. Hypotension usually occurs with rapid administration of phenytoin by the intravenous route. Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for Phenytoin. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Irritation and inflammation of soft tissue has occurred at the injection site with and without extravasation of phenytoin. Soft tissue irritation may vary from slight tenderness to extensive necrosis, sloughing and in rare instances has led to amputation. Subcutaneous or perivascular injection should be avoided because of the highly alkaline nature of the solution. The intramuscular route is not recommended for the treatment of status epilepticus because of slow absorption and the resultant delay in achieving serum levels of phenytoin in the therapeutic range. Intravenous phenytoin should be used with caution in patients with hypotension and severe myocardial insufficiency. Phenytoin should be discontinued if a skin rash appears. If the rash is exfoliative, purpuric, or bullous or if lupus erythematosus, Stevens-Johnson syndrome, or toxic epidermal necrolysis is suspected, use of this drug should not be resumed and alternative therapy should be considered. If the rash is of a milder type (measles-like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstitution of therapy, further phenytoin medication is contraindicated. Phenytoin is not effective for absence (petit mal) seizures. If tonic-clonic (grand mal) and absence (petit mal) seizures are present together, combined drug therapy is needed.
Serum levels of phenytoin sustained above the optimal range may produce confusional
states referred to as 'delirium', 'psychosis', or 'encephalopathy', or rarely irreversible
cerebellar dysfunction. Accordingly, at the first sign of acute toxicity, serum drug level
determinations are recommended. Dose reduction of phenytoin therapy is indicated if
serum levels are excessive; if symptoms persist, termination of therapy with phenytoin is
Because phenytoin is highly protein bound and extensively metabolised by the liver,
reduced maintenance dosage may be required in patients with impaired liver function to
prevent accumulation and toxicity. Where protein binding is reduced, as in uraemia, total
serum phenytoin levels will be reduced accordingly. However, as the pharmacologically
active free drug concentration is unlikely to be altered, under these circumstances
therapeutic control may be achieved with total phenytoin levels below the normal range
10 - 20mg/l. Dosage should not exceed the minimum needed to control convulsions.
Biotransformation of phenytoin occurs mainly in the liver. Patients with impaired hepatic
function, the elderly, or those who are gravely ill may show early signs of toxicity.
Phenytoin may affect glucose metabolism and inhibit insulin release.
Hyperglycaemia has been reported.
Phenytoin is not indicated for seizures due to hypoglycaemia or other metabolic causes.
Caution is advised when treating patients with diabetes.
There are isolated reports associating phenytoin with exacerbation of porphyria,
therefore, caution should be exercised when using phenytoin in patients with porphyria.
Herbal preparations containing St John's Wort (Hypericum perforatum) should not be
used while taking phenytoin due to the risk of decreased plasma concentrations and
reduced clinical effects of phenytoin (see section 4.5)
Laboratory tests: It may be necessary to measure serum phenytoin levels to achieve
optimal dosage adjustments.
This product contains a number of excipients known to have a recognized action or
effect. These are:
Propylene glycol (may cause alcohol-like symptoms)
This medicinal product contains less than 1mmol sodium (23mg) per dose i.e.
Ethanol (395.75 mg/5 ml):- This may be harmful for those suffering from alcoholism and
should be taken into account in pregnant or breast-feeding women, children and high-risk
groups such as patients with liver disease, or epilepsy 4.5 Interaction with other medicinal products and other forms of interaction
1) Drugs which may increase phenytoin serum levels include: amiodarone, antifungal agents (including amphotericin B, fluconazole, ketoconazole, miconazole and itraconazole), azapropazone, chloramphenicol, chlordiazepoxide, diazepam, dicoumarol, disulfiram, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, oestrogens, omeprazole, phenothiazines, phenylbutazone, salicylates, succinimides, sulphonamides, trazodone, viloxazine ,diltiazem, tolbutamide and nifedipine. 2) Drugs which may decrease phenytoin serum levels include: folic acid, reserpine, rifampicin, sucralfate, theophylline and vigabatrin. Serum levels of phenytoin can be reduced by concomitant use of the herbal remedy St. John’s Wort (Hypericum perforatum), and this effect may persist for at least two weeks after cessation of treatment with St. John’s Wort. 3) Drugs which may either increase or decrease phenytoin serum levels include: certain antacids, antineoplastic agents, carbamazepine, ciprofloxacin, phenobarbital, sodium valproate, valproic acid and zidovudine. The effect of phenytoin on phenobarbital, carbamazepine, sodium valproate and valproic acid serum levels is also unpredictable. Acute alcoholic intake may increase phenytoin serum levels whereas chronic alcoholic use may decrease serum levels. 4) Tricyclic antidepressants and phenothiazines may precipitate seizures in susceptible patients and phenytoin dosage may need to be adjusted. Phenytoin increases the clearance of quetiapine and thus impairing the effect of it. Neurotoxicity has been reported during concomitant use of phenytoin and lithium. 5) Drugs whose effect is impaired by phenytoin include: antifungal agents, antineoplastic agents, amprenavir, clozapine, corticosteroids, ciclosporin, dicoumarol, digitoxin, disopyramide, doxycycline, felodipine, furosemide, haloperidol, levodopa, methadone, methoxsalen, mexiletine, neuromuscular blockers, oestrogens, oral contraceptives, quinidine, rifampicin, theophylline, thyroxine, vitamin D, calcium channel blockers, lamotrigine and paroxetine. 6) Drugs whose effect may be enhanced by phenytoin include warfarin. The interaction between phenytoin and warfarin may lead to increased INR. The effect of phenytoin on warfarin is variable and prothrombin times should be determined when these agents are combined. Serum level determinations are especially helpful when possible drug interactions are suspected. Drug/laboratory test interactions
Phenytoin may cause a slight decrease in serum levels of total and free thyroxine,
possibly as a result of enhanced peripheral metabolism. These changes do not lead to
clinical hypothyroidism and do not affect the levels of circulating TSH. The latter can
therefore be used for diagnosing hypothyroidism in the patient on phenytoin. Phenytoin
does not interfere with uptake and suppression tests used in the diagnosis of
hypothyroidism. Phenytoin may cause decreased serum levels of protein-bound iodine
(PBI). It may also produce lower than normal values for dexamethasone or metapyrone
tests. Phenytoin may cause raised serum levels of glucose, alkaline phosphatase, gamma
glutamyl transpeptidase and lowered serum levels of calcium and folic acid. Phenytoin
may affect blood sugar metabolism tests.
It is recommended that serum folate concentrations be measured at least every 6 months,
and folic acid supplements given if necessary.
4.6 Pregnancy and lactation
The following information should be taken into account when considering the
intravenous use of phenytoin in the management of status epilepticus in pregnancy. It is
essential to control the condition as quickly as possible in order to reduce the potential
adverse effects, specifically hypoxia, of status epilepticus upon the foetus.
There are difficulties in obtaining meaningful data on drug teratogenicity in humans.
Genetic factors or the epileptic condition itself may be more important than drug therapy
in the development of birth defects. Most mothers on anticonvulsant therapy deliver
normal infants. In patients receiving an anticonvulsant drug to prevent major seizures, it
is important that the drug should not be discontinued because of the strong possibility of
precipitating status epilepticus and attendant hypoxia and threat to life if the drug was
withdrawn. In individual cases, where the frequency and severity of the seizure disorder
are such that cessation of therapy does not pose a serious risk to the patient,
discontinuation of the drug may be considered prior to and during pregnancy. However, it
cannot be stated with certainty that even minor seizures do not pose some hazard to the
developing embryo or foetus.
There is some evidence that phenytoin may produce congenital abnormalities in the
offspring of a small number of patients with epilepsy. Therefore, phenytoin should not be
used as a first-line drug during pregnancy, especially in early pregnancy, unless the
physician considers that the potential benefits outweigh the risk.
More recent to the reports of an increased incidence of congenital malformations such as
cleft lip/palate and cardiac malformations in children of women who received phenytoin
and other antiepileptic agents, there have been reports of foetal hydantoins syndrome.
The syndrome consists of prenatal growth deficiency, microencephaly and mental
deficiency in the children of women who received phenytoin, alcohol, barbiturates
or trimethadione. However, all of these features are interrelated and are frequently
associated with intrauterine growth retardation due to other causes.
There are isolated reports of malignancies, including neuroblastoma, in the children of
women who received phenytoin during pregnancy.
Because of altered phenytoin absorption or metabolism during pregnancy, a proportion of
patients experience an increase in seizure frequency; periodic estimations of serum
phenytoin levels serve as a valuable guide to appropriate dosage adjustment in the
management of epilepsy during pregnancy. However, restoration of the original dosage
will probably be indicated postpartum.
There have been reports of neonatal coagulation defects occurring within the first 24
hours in babies born to women receiving phenytoin. Vitamin K can be used to prevent or
correct this defect and may be administered to the mother prior to delivery and to the
neonate after birth. Phenytoin is excreted in small quantities in breast milk and breast
feeding is not recommended. 4.7 Effects on ability to drive and use machines
Patients are acutely ill and hospitalised. 4.8 Undesirable effects
Signs of toxicity are associated with cardiovascular and central nervous system
Severe cardiotoxic reactions and fatalities have been reported with atrial
and ventricular conduction depression and ventricular fibrillation. Severe complications
are seen most commonly in elderly or seriously ill patients. Respiratory:
Alterations in respiratory function including respiratory arrest may occur. Central nervous system:
The most common reactions associated with phenytoin therapy
involve the C.N.S. and are usually dose-related. These include nystagmus, ataxia,
slurred speech, decreased co-ordination, mental confusion, paraesthesia, drowsiness
and vertigo. Dizziness, insomnia, transient nervousness, motor twitching, and headache
have also been observed. There have also been rare reports of phenytoin-induced
dyskinesia, including chorea, dystonia, tremor, and asterixis, similar to those induced by
phenothiazine and other neuroleptic drugs. A predominantly sensory peripheral
polyneuropathy has been observed in patients receiving long-term phenytoin therapy.
Tonic seizures have also been reported. Injection site:
Local reactions reported include irritation, inflammation and tenderness.
Necrosis and sloughing have been reported after subcutaneous or perivascular injection
and subcutaneous or perivascular injection should, therefore, be avoided. Soft tissue
irritation and inflammation have occurred at the site of injection with and without
extravasation of intravenous phenytoin.
Dermatological manifestations sometimes accompanied by fever
have included scarlatiniform or morbilliform rashes. A morbilliform rash (measles-like)
is the most common. Other types of dermatitis are seen more rarely. Other more serious
forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, lupus
erythematosus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Haemopoietic system:
Haemopoietic complications, some fatal, have occasionally been
reported in association with administration of phenytoin. These have included
thrombocytopenia, leucopenia, granulocytopenia, agranulocytosis, and pancytopenia
with or without bone marrow suppression and aplastic anaemia. While macrocytosis and
megaloblastic anaemia have occurred, these conditions usually respond to folic acid
therapy. There have been a number of reports suggesting a relationship between
phenytoin and the development of lymphadenopathy (local or generalised) including
benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's Disease.
Although a cause and effect relationship has not been established, the occurrence of
lymphadenopathy indicates the need to differentiate such a condition from other types of
lymph node pathology. Lymph node involvement may occur with or without symptoms
and signs resembling serum sickness, e.g. fever, rash and liver involvement.
All cases of lymphadenopathy require follow-up for an extended period and every effort
should be made to achieve seizure control using alternative anticonvulsant agents. Gastrointestinal system:
Nausea, vomiting, constipation, toxic hepatitis, and liver
damage have been reported. Connective tissue system:
Coarsening of the facial features, enlargement of the lips,
gingival hyperplasia, hirsutism, hypertrichosis, Peyronie's disease and Dupuytren's
contracture may occur rarely. Immune system:
Hypersensitivity syndrome has been reported and may in rare cases be
fatal (the syndrome may include, but is not limited to, symptoms such as arthralgias,
eosinophilia, fever, liver dysfunction, lymphadenopathy or rash), systemic lupus
erythematosus, periarteritis nodosa, and immunoglobulin abnormalities may occur.
Several individual case reports have suggested that there may be an increased,
although still rare, incidence of hypersensitivity reactions, including skin rash and
hepatotoxicity, in black patients. Other:
Polyarthropathy, interstitial nephritis, pneumonitis. 4.9 Overdose
The mean lethal dose in adults is estimated to be 2 to 5 grams. The lethal dose in
children is not known. The initial signs are nystagmus, ataxia, and dysarthria. Other
signs are tremor, hyperflexia, lethargy, nausea, vomiting.
Overdosage may lead to hypotension, coma and respiratory depression. Death is due to
respiratory and circulatory depression. Attempts to relate serum levels of the drug to
toxic effects have shown wide interpatient variation.
Nystagmus on lateral gaze usually appears at 20mg/l and ataxia at 30mg/l.
Dysarthria and lethargy appear when the serum concentration is above 40mg/l, although
a serum concentration as high as 50mg/l has been reported without evidence of toxicity.
As much as 25 times the therapeutic dose, which resulted in a serum concentration of
100mg/l was taken with complete recovery.
Treatment : There is no known antidote and treatment is symptomatic and supportive.
Particular attention should be paid to circulatory and respiratory function and appropriate
supportive measures employed. Haemodialysis can be considered, since phenytoin is
not completely bound to plasma proteins.
Total exchange transfusion has been used in the treatment of severe intoxication in
children. In acute overdosage the possibility of other CNS depressants, including
alcohol, should be borne in mind. 5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Phenytoin is an anticonvulsant which appears to stabilise rather than elevate the seizure
threshold and to limit the spread of seizure activity rather than abolish the primary focus
of seizure discharge. Phenytoin exerts a stabilising effect on excitable membranes of a
variety of cells, including neurons and cardiac myocytes. 5.2 Pharmacokinetic properties
A small percentage of recipients appear to metabolise phenytoin more slowly than
normal and this appears to be genetically determined.
Absorption of phenytoin is slow from the gastro-intestinal tract and is even slower from
the intramuscular site. Phenytoin is widely distributed throughout the body and is
extensively (about 90%) bound to plasma proteins. It has a very variable dose dependent
half-life but the mean appears to be about 22 hours at steady-state.
Phenytoin is extensively metabolised in the liver to inactivate metabolites. It undergoes
enterohepatic recycling and is excreted in the urine, mainly as metabolites. Phenytoin
crosses the placenta and small amounts are excreted in breast milk. 5.3 Preclinical safety data
No further relevant information other than that which is included in other sections of the
Summary of Product Characteristics. 6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Propylene Glycol B.P.
Sodium Hydroxide B.P.
Water for Injections B.P. 6.2 Incompatibilities
Phenytoin has a pH in the range of 10 - 12.3. It will only stay in solution when the pH is
considerably alkaline (about 10 - 12). The mixing of phenytoin sodium injection with
other drugs is not recommended. 6.3 Shelf life
If only part used, discard the remaining solution. 6.4 Special precautions for storage
Do not store above 30°C.
Keep the ampoule in the outer carton in order to protect from light. 6.5 Nature and contents of container
5ml, clear glass ampoules, glass type I, Ph. Eur. packed in cardboard cartons to contain
10 x 5ml ampoules. 6.6 Special precautions for disposal
For I.V. and I.M. administration.
Use as directed by the physician.
Solutions in which a haziness or precipitate develops should not be used.
Do not mix with other drugs because of precipitation of phenytoin acid. 7 MARKETING AUTHORISATION HOLDER
Antigen International Ltd.,
Ireland. 8 MARKETING AUTHORISATION NUMBER(S)
PL 02848/0164 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorization: 29/11/91.
10 DATE OF REVISION OF THE TEXT
13 August 2010
Timeline of the Kings of Jerusalem & Samaria 1 Timeline of the Kings of Jerusalem & Samaria Written by: Rami Nir - Israel 2007. © Edited by: Abstract: This article provides a timeline of the Kings of Jerusalem (Judah) and Samaria (Israel). The author uses various methods to scale the timeline and map it to the Biblical sources – “Kings” 1+2 and “Chronicles” 1
CHAPTER 16b: SEXUALLY TRANSMITTED DISEASES (STDs) I. Viral Infections A. Pathogens : Viruses, bacteria, and other organisms that cause disease. B. Viruses : Incapable of independent reproduction. They reproduce only inside a living host cell—obligate intracellular parasites. 1. Virus particles are generally very small, about ten times smaller than a bacterium. 2. Composed of an